Cellular Biomedicine Group (CBMG) will begin picking the patients to test anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.
The company said this Phase I clinical study will enroll 22 patients with relapsed and/or refractory Multiple Myeloma to test the safety and efficacy of C-CAR088, anti-BCMA Chimeric Antigen Receptor T-Cell therapy.
Tony (Bizuo) Liu, cellular’s CEO said: “As a drug development company, BCMA is the first of multiple assets that CBMG is advancing amongst our oncology pipeline beyond our collaboration with a global leader in cell therapy. We plan to provide updates in the near future on the progress of our other proprietary technologies, including anti-CD22 and anti-CD20 CAR-T targeting relapsed Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-cell Lymphoma (DLBCL) patients post anti-CD19 CAR-T treatment, Alpha Fetoprotein T-cell Receptor (AFP-TCR-T) for Hepatocellular Carcinoma, and next generation Tumor Infiltrating Lymphocytes (TIL) for the treatment of non-small cell lung cancer (NSCLC) and other solid tumor indications. We hope to be able to provide expeditious, safe and effective therapies to cancer patients who currently have limited treatment options.”